Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Abbott wins FDA clearance for CardioMEMS HF System update enabling heart failure patients to monitor pulmonary artery pressure at home
Medical device, cardiovascular, heart failure, pulmonary artery pressure, remote monitoring - Read more

Catalent, Ori Biotech partner to integrate Iro platform for automated cell therapy manufacturing
Manufacturing agreement, cell therapy, gene therapy, automation, CDMO - Read more

TychoBio, PacBio partner to generate long-read RNA sequencing data for rare disease AI drug development
Research collaboration, rare disease, AI/ML, RNA therapy, drug discovery - Read more

Alvotech, LOTTE Biologics announce long-term US manufacturing partnership to expand global biosimilar supply
Manufacturing agreement, biosimilars, antibody, CDMO - Read more

Halozyme Therapeutics, Argenx expand ENHANZE collaboration to include two additional subcutaneous delivery targets
Licensing deal, autoimmune, subcutaneous delivery, milestone payments, royalties - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

GSK's Cabenuva (cabotegravir/rilpivirine) shows superior viral suppression in unsuppressed HIV patients in Ph3 trial
Small molecule, infectious disease, HIV, antiretroviral therapy, long-acting injectable, viral suppression - Read more

Atsena Therapeutics' (ATSN-201) shows Ph1/2/3 efficacy in X-linked retinoschisis, supporting potential 2028 FDA filing
Gene therapy, eye disease, X-linked retinoschisis, retinal gene therapy, rare disease - Read more

Cerevance's (solengepras) meets Ph3 primary endpoint, reducing off time in Parkinson's disease, paving path to FDA
Small molecule, neurological, Parkinson's disease, GPR6 receptor, adjunct therapy, motor fluctuations - Read more

Matchpoint Therapeutics raises $150M Series B to advance covalent medicines pipeline into clinic
Autoimmune, small molecule, covalent therapeutics, clinical-stage - Read more

TCGX launches $600M Asia Life Sciences Fund I to invest in Asian biotechs
Venture capital, biotech investment, drug discovery, crossover investing - Read more

Lycia Therapeutics files for IPO, advancing extracellular protein degraders for autoimmune and allergic diseases
Targeted protein degradation, autoimmune, allergic disease, antibody-small molecule conjugate, clinical-stage - Read more

Sensible Biotechnologies raises $47M Series A to scale next-gen cell-based mRNA manufacturing platform
mRNA therapeutics, platform technology, AI-driven, manufacturing, cell therapy - Read more

KymaThera raises $80M Series B to advance PI3Kα inhibitor K-1728 into clinical trials
Oncology, small molecule, breast cancer, clinical-stage, structure-based drug discovery - Read more

Multiply Labs raises $75M Series B, automating biologics manufacturing with physical AI robotics
Manufacturing, robotics, biologics, AI-driven, CDMO - Read more

ARPA-H launches Surpass program to modernize clinical trials through adaptive, AI-driven infrastructure
Clinical trial design, multiple diseases, adaptive trials, artificial intelligence, drug development - Read more

NICE recommends Sobi's Tryngolza for ultra-rare familial chylomicronaemia syndrome in England and Wales
Antisense oligonucleotide, rare disease, regulatory, cardiovascular - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

MimiVax's SurVaxM (survaxm) fails Ph2 primary endpoint in newly diagnosed glioblastoma multiforme
Vaccine, cancer, peptide vaccine, glioblastoma, survivin target - Read more

Caribou Biosciences halts CAR-T programs, cuts staff, seeks strategic alternatives amid funding challenges
CAR-T, oncology, strategic, cost reduction - Read more

Nuvig Therapeutics halts Ph2 trial of (NVG-2089) fusion protein for chronic inflammatory demyelinating polyradiculoneuropathy amid enrollment challenges
Protein therapy, autoimmune, fusion protein, chronic inflammatory demyelinating polyradiculoneuropathy, immune thrombocytopenia - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here